INTRODUCTION
Autologous or allogeneic G-CSF-mobilized peripheral blood is an important source of hematopoietic progenitor cells (HPCs) for subsequent transplantation in various hematological diseases, but the therapeutic success to mobilize sufficient numbers of CD34 + cells is limited in a number of patients, in part due to their refractoriness or poor response to G-CSF 1 . Therefore, a better understanding of the underlying mechanisms regulating HPC mobilization in response to G-CSF might offer novel therapeutic opportunities for HPC mobilization.
Studies in mice genetically deficient for G-CSF or its receptor (G-CSF-R) have shown that G-CSF does not mobilize HPCs by binding to its receptor on these cells but, instead, by
binding to G-CSF-R + resident cells within the bone marrow (BM) microenvironment and stimulating HPC mobilization via paracrine signals 2 . Other studies underscored an important role for BM-derived proteinases, such as neutrophil elastase and MMP-9, which inactivate adhesive signals anchoring HPCs in the BM [3] [4] [5] [6] . However, loss of these proteinases did not necessarily impair HPC mobilization after G-CSF 7, 8 .
Using gene deficient mice, we recently documented a role for the proteinase plasmin in HPC mobilization in response to G-CSF 9 . Plasmin is generated from its zymogen plasminogen via proteolytic cleavage by two plasminogen activators (PA), i.e. tissue-type PA (tPA) and urokinase-type PA (uPA), whereas inactivation of plasmin occurs by α2-antiplasmin (AP) and its generation is prevented by PAI-1 (which neutralizes PA activity) (reviewed in 10 ). Apart from regulating hemostasis, plasmin also cleaves cell-surface receptors, activates matrix metalloproteases (MMPs), remodels the extracellular matrix and liberates matrix-bound growth factors, explaining why this proteinase system has such a pleiotropic role in tissue healing, regeneration and malignancy 10 . A recent report showed that administration of recombinant human tPA promotes the hematopoietic recovery of myeloablated mice, but the authors did not investigate its effects on HPC mobilization following G-CSF therapy 11 . Here, we investigated whether plasmin could enhance HPC mobilization in response to G-CSF.
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EXPERIMENTAL METHODS

Animal studies
All experiments were performed according to the guidelines for care and use of laboratory animals approved by the institutional ethical animal care committee.
Patient study
The protocol of this non-randomized clinical study was approved by the local medical ethical committee (ML2526) and was performed in accordance with the Declaration of Helsinki.
Please see supplement for full Experimental Methods section.
RESULTS AND DISCUSSION
GENETIC LOSS OF PAI-1 OR α2-ANTIPLASMIN INCREASES HPC MOBILIZATION
We first analyzed mobilization of HPCs in response to G-CSF in mice lacking PAI-1 
THROMBOLYTIC AGENTS ENHANCE HPC MOBILIZATION IN MICE
The results above indicate that plasmin augments G-CSF-mediated mobilization. We therefore evaluated whether thrombolytic compounds, that generate or increase plasmin,
For personal use only. on April 9, 2017. by guest www.bloodjournal.org From and which are currently being used in the clinic (tenecteplase, recombinant human tPA) or are in clinical development (microplasmin, staphylokinase) might be useful to stimulate HPC mobilization. For the mouse study, we used three thrombolytics: recombinant human tPA (rtPA), tenecteplase (TNK; a rtPA mutant which has a prolonged half-life and is used for treatment of acute cardio-and cerebro-vascular syndromes), and micro-plasmin (µPli; a plasmin variant lacking the five aminoterminal kringle domains, which has an improved safety profile (less bleeding) and is easier to produce as recombinant protein than plasmin 12 ). Since mice are well known to be ~10-fold less responsive to these thrombolytic agents, especially when given as intraperitoneal bolus injection (discussed further below; It is well known that human rtPA has a short half-life in mice (i.e. in the order of minutes 16 ), resulting from its rapid sequestration by mouse PAI-1 and a low efficiency to convert mouse plasminogen to plasmin (>40-fold lower than for human plasminogen 13-15 );
we therefore used a 10-fold higher dose than normally administered to humans [13] [14] [15] .
Nonetheless, daily intraperitoneal bolus injection of human rtPA (100 mg/kg) failed to enhance HPC mobilization in steady-state conditions or following G-CSF administration in mice (not shown). Our data thus differ from recent findings by Heissig et al. that a 100-fold lower dose of human rtPA in mice increases HPC mobilization in steady-state conditions and after chemo-myeloablation 11 ; the precise reason for this discrepancy remains unexplained.
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THROMBOLYTIC AGENTS ENHANCE HPC MOBILIZATION IN HUMANS
We also evaluated whether thrombolytic agents would be capable of inducing HPC mobilization in humans as well. Our mouse results indicate that thrombolytic agents only enhance HPC mobilization, when these cells are already primed by another mobilization stimulus (such as G-CSF). However, ethical reasons precluded us from testing whether thrombolytic agents enhance HPC mobilization in response to G-CSF in healthy volunteers.
We therefore studied the effect of thrombolytic agents in the setting of acute myocardial ischemia, as this is a well-known stimulus for HPC mobilization 17 . Therefore, peripheral blood samples were collected before and 24 hours after thrombolytic treatment (TNK or staphylokinase) of patients, who were admitted to the Coronary Care Unit with ST-segment elevation myocardial infarction (STEMI). As control group, blood samples were collected from STEMI patients before and 24 hours after percutaneous coronary intervention (PCI), since this procedure does not induce HPC mobilization at this early time point i.e. at 3-7 days after treatment 17, 18 . In contrast, thrombolytic therapy significantly increased HPC mobilization at 24 hours after treatment. Compared to the pre-treatment levels, corresponding values after thrombolytic therapy were: 690 ± 230% for the CFU-Cs (P<0.05)
For personal use only. on April 9, 2017. by guest www.bloodjournal.org From and 385 ± 75% for the CD34 + cells (P<0.005). Taken together, even though only a small number of patients was analyzed in a non-randomized study design (and larger cohorts will have to be analyzed in the future), these findings suggest that thrombolytic agents enhance the mobilization of HPCs in STEMI patients at 24 hours after myocardial infarction.
CONCLUSIONS
The main finding of this study is that plasmin augments HPC mobilization following G-CSF. Our findings that fibrinolytic agents stimulate HPC mobilization warrant further exploration of their therapeutic potential in individuals who mobilize poorly in response to G-CSF. Especially the use of micro-plasmin might be recommended in perspective of its reduced risk to induce bleeding 12 .
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